A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials

The tremendous success of chimeric antigen receptor (CAR) T cells in children and young adults (CAYAs) with relapsed/refractory B-cell acute lymphoblastic leukemia is tempered by toxicities such as cytokine release syndrome (CRS). Despite expansive information about CRS, profiling of specific end-or...

Descripción completa

Detalles Bibliográficos
Autores principales: Silbert, Sara K., Madan, Sanna, Holland, Elizabeth M., Steinberg, Seth M., Little, Lauren, Foley, Toni, Epstein, Monica, Sarkisian, Angela, Lee, Daniel W., Nikitina, Ekaterina, Kakumanu, Showri, Ruppin, Eytan, Shalabi, Haneen, Yates, Bonnie, Shah, Nirali N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514106/
https://www.ncbi.nlm.nih.gov/pubmed/37486616
http://dx.doi.org/10.1182/bloodadvances.2023009789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514106/
https://www.ncbi.nlm.nih.gov/pubmed/37486616
http://dx.doi.org/10.1182/bloodadvances.2023009789

Ejemplares similares